A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •For participants receiving erlotinib group: prior treatment with any EGFR mutant-targeting TKI
• •Any approved anticancer therapy, including chemotherapy, or hormonal therapy (except hormone-replacement therapy or oral contraceptives) within 3 weeks of first dose.
• •Treatment with any other test drug or participation in another clinical trial within 28 days of enrollment.
• •Known symptomatic central nervous system (CNS) metastases. Participants with a history of treated or untreated asymptomatic CNS metastases may be eligible.
• •Leptomeningeal disease.
• •Uncontrolled tumor-related pain.
• •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage at least once monthly.
• •High levels of calcium requiring bisphosphonate therapy or denosumab.
• •Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in-situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ).
• •History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins.
• •Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
• •History of autoimmune disease.
• •Participants with prior bone marrow or solid organ transplantation.
• •History of lung inflammation or disease.
• •Serum albumin less than (\<) 2.5 grams per deciliter (g/dL).
• •Positive for Human Immunodeficiency Virus (HIV).
• •Liver disease.
• •Current or active tuberculosis, hepatitis B, or hepatitis C.
• •Participants with past or resolved hepatitis B virus (HBV) infection are eligible; participants positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV Riboxy Nucleic Acid (RNA).
• •Signs or symptoms of infection within 2 weeks prior to first dosing.
• •Received therapeutic oral or IV antibiotics within 2 weeks prior to first dosing.
• •Significant cardiovascular disease.
• •Major surgical procedure other than for diagnosis within 28 days prior to first dosing or during the course of the study.
• •Administration of a live, attenuated vaccine within 4 weeks before first dosing or during the study.
• •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may reasonably prevent the participant from participating.
• •Hypersensitivity to erlotinib or alectinib or to any of the excipients.
• •Any significant ophthalmologic abnormality. The use of contact lenses is not recommended during the study.
• •For participants receiving alectinib: baseline Fridericias corrected QT interval (QTcF) greater than (\>) 470 milliseconds (ms) or symptomatic bradycardia.
• •Prior treatment with CD137 agonists or immune checkpoint blockade therapies.
• •Treatment with systemic immunostimulatory agents within 6 weeks or five half-lives of the drug, whichever is shorter, prior to first dosing.
• •Treatment with systemic immunosuppressive medications within 2 weeks prior to first dosing (inhaled corticosteroids and mineralocorticoids are allowed).
• •Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication are elgible for study after discussion and approval by the Medical Monitor.